Ardelyx, Inc. (ARDX): Total Liabilities
$334.65M
As of 2025-12-31
$426.88M
As of 2026-06-30
+53.9%
3-year compound annual growth
+34.7%
5-year compound annual growth
+45.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $334.65M | +27.5% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $262.46M | +100.7% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $130.76M | +42.5% | 2025-02-20, Balance as of period end |
| 2022-12-31 | $91.74M | +36.3% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $67.30M | -10.8% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $75.45M | +3.2% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $73.13M | +8.3% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $67.52M | +263.2% | 2020-03-06, Balance as of period end |
| 2017-12-31 | $18.59M | -7.0% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $19.98M | +148.4% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $8.04M | -84.7% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $52.73M | +5.0% | 2016-03-04, Balance as of period end |
| 2013-12-31 | $50.23M | n/a | 2015-03-05, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $2.15B | +5.0% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $456.88M | +32.5% |
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
Compare ARDX, SVA, ARQT, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗